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Matrix Metalloproteinases
in Atrial Fibrillation
We read with great interest the study by Boixel et al. (1), which
examines the importance of matrix metalloproteinase (MMP)
system in atrial remodeling in a rat model of heart failure. The
investigators demonstrate the up-regulation of MMP-2 and
MMP-9 in the atria with marked structural abnormalities, but
there were no significant differences in tissue inhibitors of MMP
(TIMP) activity.
The clinical significance of the report by Boixel et al. (1)
requires clarification in a (human) patient population. We recently
explored plasma levels of MMP-1 and TIMP-1 in 48 consecutive
patients with chronic nonrheumatic atrial fibrillation (AF) (2) and
found evidence of impaired matrix degradation, with lower levels
of MMP-1 and increased levels of TIMP-1 compared with
controls. However, these values were not independently associated
with the presence of AF on multivariate analysis. Instead, clinical
(i.e., age, ischemic heart disease, or hypertension) and echocardio-
graphic variables (end-diastolic left ventricular diameter or left
ventricular mass index) were found to be independently associated
with MMPs. In a preliminary study, decreased MMP-1 activity
was found in the atria of AF patients undergoing open-heart
surgery (3).
There are controversial data whether structural changes in the
atria are related to AF (4,5) or to underlying diseases (6,7). Our
findings (2) and those of Boixel et al. (1) suggest that increased
interstitial fibrosis in atrial tissue is more likely due to underlying
comorbidities, like hypertension, ischemic heart disease, or uncon-
trolled heart failure (circumstances associated with high risk to
develop AF), than to the presence of arrhythmia itself. Moreover,
experimental data suggest that underlying diseases promote AF by
causing atrial interstitial fibrosis (8). Certainly, decreased con-
centration of MMP-1 (the most important enzyme in the extra-
cellullar degradation of collagen types I and III) with raised levels
of TIMP-1 have been observed in hypertensive patients (9). In this
setting, TIMP-1 has been recently proposed as a noninvasive
marker of fibrosis in a large cohort of untreated hypertensive
subjects (10).
Finally, the possible relationship of the MMP system to the
thromboembolic risk in AF merits exploration. For example, an
independent relationship was observed between the MMP system
and the prothrombotic state in AF (as assessed by prothrombin
fragment 1  2 levels) (2).
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REPLY
Marı´n and collaborators report that, in patients in atrial fibrillation
(AF), plasma level of MMP-1 is decreased while that of TIMP-1
is increased, suggesting an impaired matrix degradation in this
clinical setting (1). Because alteration in the MMP/TIMP system
correlates with left ventricular mass and remodeling but not with
AF, the investigators conclude that the atrial fibrosis is caused by
the underlying diseases. This is in agreement with our studies in a
rat model of heart failure with atrial dilation (2) or in human right
appendages (3) showing that structural alterations of the atrial
myocardium are associated with left ventricle dysfunction, inde-
pendently of AF.
An apparent controversy exists between the decreased MMP-1
and increased TIMP-1 in plasma of patients in AF (1) and the
up-regulation of MMP-2 and MMP-7 (and not MMP-9 see the
letter of Marı´n et al) but not of TIMPs in our model (2). One
explanation is probably that we studied protease activity in tissue
and not in plasma. This point is crucial for MMP-7, which is
anchored to cell basement membrane, thus preventing its diffusion
and probably any increase in the plasma (4).
Myocardial fibrosis is a dynamic process during which normal
collagen chains are degraded and replaced by fibrous interstitial
deposits. The MMPs are involved both in matrix degradation and
collagen synthesis (5). Thus, their up-regulation in dilated rat atria
suggests an ongoing activation of processes leading to matrix
remodeling. This may not be the case in patients with long-lasting
history of AF and a therapeutically controlled hypertension or
heart failure (1). A time-dependent MMP activation is well known
during the progression of cardiopathies. Acute pressure overload
induces myocardial MMP activation that normalizes with the
prolongation of the pressure overload (6). Distinct regulations of
152 Letters to the Editor JACC Vol. 43, No. 1, 2004
January 7, 2004:151–3
